When should a SGLT‑2 inhibitor be started, dose‑adjusted, or discontinued based on a patient's estimated glomerular filtration rate (eGFR)?

SGLT-2 Inhibitor eGFR Thresholds for Initiation and Continuation

Initiate SGLT-2 inhibitors when eGFR ≥20 mL/min/1.73 m² and continue them even if eGFR falls below 20 mL/min/1.73 m² until dialysis or transplantation is initiated. This represents the most current evidence-based approach to maximizing cardiorenal protection while maintaining safety 1.

When to Start SGLT-2 Inhibitors

Initiation Threshold: eGFR ≥20 mL/min/1.73 m²

The 2025 KDOQI commentary on KDIGO 2024 guidelines establishes eGFR ≥20 mL/min/1.73 m² as the initiation threshold 1. This is a significant update from the 2020 KDIGO guideline that recommended eGFR ≥30 mL/min/1.73 m² 2.

Prioritize initiation based on these high-risk features:

• Albuminuria ≥200 mg/g (≥20 mg/mmol) - strongest indication 1
• Heart failure (regardless of ejection fraction or albuminuria level) 1
• eGFR 20-45 mL/min/1.73 m² with albuminuria <200 mg/g - weaker but still beneficial 1

The 2022 ADA guidelines support SGLT-2 inhibitors down to eGFR ≥20 mL/min/1.73 m² with evidence from DAPA-CKD and EMPEROR trials 3. Recent 2025 meta-analysis data confirm efficacy across all eGFR ranges, including stage 4 CKD 4.

Agent Selection

Choose SGLT-2 inhibitors with proven kidney and cardiovascular benefits 2, 1:

• Canagliflozin 100 mg daily
• Dapagliflozin 10 mg daily
• Empagliflozin 10 mg daily

These three agents have demonstrated outcome benefits in dedicated kidney disease trials 1, 5.

Dose Adjustments Based on eGFR

No Dose Adjustment Required

• eGFR ≥45 mL/min/1.73 m²: Use standard doses without modification 6

Modified Dosing for Lower eGFR

Canagliflozin:

• eGFR 30-59 mL/min/1.73 m²: Maximum 100 mg daily 6, 7
• eGFR 20-29 mL/min/1.73 m²: Continue 100 mg if already initiated 7

Dapagliflozin:

• eGFR ≥25 mL/min/1.73 m²: 10 mg daily 7
• eGFR 20-24 mL/min/1.73 m²: May continue if already initiated 7

Empagliflozin:

• Can be initiated with eGFR >20 mL/min/1.73 m² based on EMPEROR trial data 3

When to Continue vs. Discontinue

Continue SGLT-2 Inhibitors When:

Once initiated, continue SGLT-2 inhibitors even if eGFR falls below 20 mL/min/1.73 m² 1, 2. This is a critical practice point supported by:

• Post-hoc analysis of CREDENCE showing persistent benefit when eGFR fell <20 mL/min/1.73 m² (HR 0.87 for primary outcome) 8
• Real-world Taiwanese cohort demonstrating reduced adverse kidney events, heart failure, and mortality with continuation 9
• FDA removal of dialysis discontinuation requirement from dapagliflozin label after safety review 1

The expected initial eGFR dip of 3-5 mL/min/1.73 m² within the first 4 weeks is NOT an indication to discontinue 2, 1, 2. This reversible decline is hemodynamic and does not represent true kidney injury.

Discontinue SGLT-2 Inhibitors When:

Absolute indications to stop:

• Dialysis initiation (hemodialysis or peritoneal dialysis) 2, 1
• Kidney transplantation 2
• Drug intolerance (persistent genital infections, recurrent ketoacidosis) 2

Temporarily withhold during:

• Prolonged fasting, surgery, or critical illness (increased ketoacidosis risk) 2, 1, 2
• Acute illness with poor oral intake 5

Pre-Initiation Risk Mitigation

Volume Status Assessment

If patient is at risk for hypovolemia 2, 5:

• Reduce thiazide or loop diuretic doses before starting SGLT-2 inhibitor
• Counsel on volume depletion symptoms (dizziness, orthostasis)
• Follow up on volume status after initiation

Real-world data show extreme eGFR reductions can occur in volume-sensitive patients on concomitant loop diuretics 10.

Hypoglycemia Risk Management

For patients on insulin or sulfonylureas at glycemic target 2:

• Reduce insulin or sulfonylurea dose before adding SGLT-2 inhibitor
• Do NOT reduce metformin dose
• Monitor for hypoglycemia after initiation

Ketoacidosis Prevention

Educate patients on sick day rules 5:

• Temporarily stop SGLT-2 inhibitor during illness
• Maintain at least low-dose insulin if on insulin therapy
• Check blood glucose AND ketones during illness
• Seek immediate care if ketones ≥1.0 mmol/L

Monitoring After Initiation

Do NOT increase monitoring frequency solely because of SGLT-2 inhibitor initiation 1. The initial eGFR dip does not require intervention.

Standard CKD monitoring applies:

• eGFR ≥60 mL/min/1.73 m²: Monitor at least annually 2
• eGFR 45-59 mL/min/1.73 m²: Monitor every 3-6 months 2
• eGFR 30-44 mL/min/1.73 m²: Monitor every 3-6 months 2

Common Pitfalls to Avoid

1. Do not discontinue for initial eGFR dip - This is expected and beneficial long-term 2, 1
2. Do not wait for eGFR to stabilize before initiating - Earlier initiation provides greater cumulative benefit 11
3. Do not stop when eGFR falls below initiation threshold - Continue until dialysis 1, 8
4. Do not reduce metformin when adding SGLT-2 inhibitor - Only reduce insulin/sulfonylureas if at glycemic target 2
5. Do not avoid in older patients with lower eGFR - Benefits persist across age groups and eGFR ranges 4

Special Populations

Kidney transplant recipients: SGLT-2 inhibitors have not been adequately studied; the recommendation does not apply due to immunosuppression and infection risk 2.

Post-acute kidney injury: Recent 2026 data suggest SGLT-2 inhibitor initiation within 30 days after dialysis-requiring AKI is associated with fewer adverse kidney events compared to delayed initiation 11.